Clinical Trial

Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

Recruiting

Record status

This record was last updated August 7, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Trial Details

NCT Number	NCT07109765
Lead Sponsor	Peking Union Medical College
Conditions	Hidradenitis Suppurativa (HS)
Enrollment	50 participants
Start Date	2025-06-01
Primary Completion	2026-06-01 (estimated)
Study Completion	2026-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-07